Elsevier

Epilepsy & Behavior

Volume 4, Issue 5, October 2003, Pages 537-547
Epilepsy & Behavior

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

https://doi.org/10.1016/j.yebeh.2003.07.008Get rights and content

Abstract

Levetiracetam (LEV) was shown to be very efficacious and well tolerated as add-on therapy for refractory epilepsy. Here we report 33 patients with longstanding histories of epilepsy who experienced aggressive episodes during LEV therapy. This corresponds to 3.5% of LEV-treated patients as compared with less than 1% of patients not on LEV. Among these cases, 24 showed only moderate, partly transient irritability, with 10 patients requiring reduction or discontinuation of LEV. More strikingly, 9 patients displayed severe symptoms of aggression with physical violence and, in 2 cases, the need for psychiatric emergency treatment. One patient developed additional psychotic symptoms. We suggest that, specifically in patients with a previous history of aggression, behavioral tolerability of LEV should be carefully monitored.

Introduction

Levetiracetam (LEV) was approved in the United States in November 1999 as add-on therapy for the treatment of partial-onset seizures in adults and was introduced in the Clinic for Epileptology Bonn in the year 2000. Its mode of action is still unknown and cannot be explained by mere interaction with the benzodiazepine receptor [1], [2]. LEV is not metabolized via the liver, displays very low protein binding [3], and has therefore only little interaction with other antiepileptic drugs (AEDs). LEV medication can be rapidly raised and its starting dose is effective [for review see 4].

A favorable safety profile has been demonstrated in placebo-controlled clinical trials [[5], [6], [7], [8], [9]; for review on tolerability see [10], [11]]. Treatment-emergent adverse effects were confined mainly to the central nervous system and included somnolence/asthenia, dizziness, and coordination difficulties (ataxia, abnormal gait). In particular, unwanted behavioral effects were observed in 13.3% of the cases (vs 6.2% in the placebo group). The latter comprised agitation and hostility as well as anxiety, apathy, emotional instability, depersonalization, and depression. Psychotic symptoms occurred in 0.7% of the patients treated with LEV as compared with 0.2% of the placebo group [9].

Concerning behavioral changes seen in clinical practice, the literature on LEV is still rather limited. Both favorable and unfavorable effects have been reported. A potential to provoke psychosis was indicated in a case report of four children developing psychotic symptoms under LEV medication [12]. Also in the pediatric field, a positive effect on the behavior of autistic children has been observed [13]. Aggressiveness in these children was improved if they had no medication prior to LEV. Yet, if risperidone, desipramine, or carbamazepine (CBZ) was reduced simultaneously with the introduction of LEV there was a tendency toward worsened aggressiveness under LEV. A case study suggested that LEV may be efficacious in the treatment of acute mania [14]. Cramer et al. [15] showed a general improvement of epilepsy-related quality of life. The study pointed out the positive cognitive profile of LEV. An increase in aggressiveness has so far only been evoked in the context of general tolerability in clinical trials [9], [16]. A growing interest in scrutinizing LEV and specific behavioral effects was recently revealed in the American Epilepsy Society annual meetings in 2001 and 2002 [for abstracts see [17], [18], [19], [20]].

In general, irritability and aggression are not uncommon in epileptic patients. Undirected, poorly controlled violent acts often take place peri-ictally, i.e., within hours before and after a seizure [21], [22], and may be associated with psychotic symptoms [23]. Interictal aggression may result from the use of antiepileptic drugs [24] but also from subclinical interictal epileptic activity, structural lesions, psychiatric comorbidity, mental retardation, and low socioeconomic status [22], [25], [26], [27], [28], [29], [30], [31]. Therefore, care must be taken when differentiating between drug related effects and the impact of the medical, psychiatric, and social context of epileptic disease.

Here we intend to share our clinical experience with treatment-emergent adverse effects of LEV. We present a chart review of 33 patients who developed mild to severe symptoms of irritability and aggression under LEV.

Section snippets

Selection of patients

In this report of 33 cases of aggressive behavior, patients were selected according to a computer-based library of medical records. We used a search engine that selected all records containing both levetiracetam/Keppra and aggressive/aggression or irritable/irritability. All patients except one were known to the clinic for at least one consultation prior to the administration of LEV; most of them already had multiple consultations in our clinic. Pediatric patients were not included in this

Efficacy of LEV treatment

The 33 patients presented in this study had longstanding histories of refractory epilepsy (3–45 years), with drug resistance defined as the unsuccessful trial of at least two different AEDs. Thirty patients had simple and/or complex partial seizures, 25 of these with secondary generalization. Two of the latter had become seizure-free after epileptic surgery. The remaining three patients had primary generalized epilepsy.

After LEV was increased to efficacious levels, one or two previously

Discussion

In this study, we have presented 33 patients who developed mild to severe aggressiveness in the course of LEV treatment. The incidence of this adverse effect amounts to approximately 3.5%. As to the efficacy of LEV, a major benefit was observed in 10 of these 33 patients. The largest group of patients presented here (n=14) displayed only moderate symptoms of irritability and continued LEV treatment because of satisfying seizure control. In an additional 10 cases, LEV was reduced or discontinued

Acknowledgments

We thank A. Flender for his work on the patients’ statistics.

References (49)

  • J.W Hawkins et al.

    A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias

    Am. J. Geriatr. Psychiatry.

    (2000)
  • N Lindberg et al.

    Human impulsive aggression: a sleep research perspective

    J. Psychiatr. Res.

    (2003)
  • I.E Leppik

    The place of levetiracetam in the treatment of epilepsy

    Epilepsia

    (2001)
  • M Privitera

    Efficacy of levetiracetam: a review of three pivotal clinical trials

    Epilepsia

    (2001)
  • E Ben Menachem et al.

    Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

    Epilepsia

    (2000)
  • J.J Cereghino et al.

    Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

    Neurology

    (2000)
  • S.D Shorvon et al.

    Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures

    Epilepsia

    (2000)
  • C Harden

    Safety profile of levetiracetam

    Epilepsia

    (2001)
  • E.H Kossoff et al.

    Levetiracetam psychosis in children with epilepsy

    Epilepsia

    (2001)
  • T.A Rugino et al.

    Levetiracetam in autistic children: an open-label study

    J. Dev. Behav. Pediatr.

    (2002)
  • J.F Goldberg et al.

    Levetiracetam for acute mania

    Am. J. Psychiatry

    (2002)
  • J.A Cramer et al.

    Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group

    Epilepsia

    (2000)
  • N.M Rickles et al.

    Possible association of behavioral disturbances with levetiracetam: Report of a case series

    Epilepsia

    (2001)
  • J.J Asconapé et al.

    Behavioral changes associated with levetiracetam use in patients with epilepsy

    Epilepsia

    (2001)
  • Cited by (0)

    View full text